New NIH Office to Advance Alternatives to Animal Testing
The National Institutes of Health (NIH) has established a new office dedicated to accelerating the development and adoption of human-based research methods that can reduce reliance on animal testing in biomedical research. The new Office of Research Innovation, Validation, and Application (ORIVA) will coordinate NIH-wide efforts to develop, validate, and scale innovative research technologies such as organoids, organ-on-a-chip systems, computational models, artificial intelligence, and real-world human data.
ORIVA will reside within the NIH Office of the Director and is intended to coordinate research, funding, training, and validation activities that support the broader use of what NIH refers to as New Approach Methodologies (NAMs). These include advanced laboratory models derived from human tissues, sophisticated computer simulations, and AI-driven approaches designed to better predict human biology and disease while reducing dependence on animal models.
The initiative builds on NIH's April 2025 commitment to prioritize human-based research technologies and follows a parallel effort by the U.S. Food and Drug Administration (FDA) to reduce animal testing requirements for certain drug development programs. Together, the agencies are seeking to encourage scientifically validated alternatives that may improve the predictive value of preclinical research while maintaining rigorous standards for safety and effectiveness.
NIH Director Dr. Jay Bhattacharya has described the initiative as an opportunity to "usher in a new era of innovation" by integrating advances in data science, engineering, and human biology into biomedical research. In addition to supporting new technologies, NIH plans to expand investigator training, incorporate expertise in alternative methods into grant review processes, and encourage funding opportunities that consider both animal and non-animal research approaches where scientifically appropriate. For the life sciences industry, the initiative signals growing federal support for technologies that have attracted significant investment in recent years, including organoids, microphysiological systems ("organs-on-chips"), computational toxicology, and AI-enabled disease modeling. Many biotechnology companies are already developing these platforms to complement - or in some cases replace - traditional animal studies during drug discovery and preclinical development.
At the same time, NIH emphasizes that the transition will be gradual. While alternative methods continue to advance rapidly, animal models remain necessary for many areas of biomedical research where validated human-based substitutes do not yet exist. The agency has indicated that future funding decisions will increasingly encourage investigators to consider the most scientifically appropriate model for each research question rather than defaulting to animal studies.
For Michigan's research institutions and biotechnology companies, ORIVA represents another indication that federal biomedical research is evolving toward more predictive, human-relevant technologies. Organizations developing advanced cell models, AI-driven drug discovery tools, precision medicine platforms, and other next-generation research technologies may find expanding opportunities as NIH integrates these approaches into its research portfolio.
